Drug Trial Radar · NCT06560138
A Trial of SHR-4602 Infusion in Patients With SHR-4602 in Subjects With HER2-expressing or HER2-mutated Locally Advanced or Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jan 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Mar 1, 2025
Primary completion
Dec 14, 2025
Study completion Sep 12, 2026
Sponsor
- Lead sponsor
- Atridia Pty Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SHR-4602 in subjects with HER2-expressing or HER2-mutated locally advanced or metastatic solid tumors.
Conditions
- HER2-expressing or HER2-mutated Locally or Metastatic Solid Tumors
Interventions
SHR-4602Drug
SHR-4602 will be administered through IV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- the phase II dose (RP2D) of SHR-4602Time frame: From the time when the subjects sign the informed consent form to 45(±3) days after the last dose of SHR-4602, or the start of new anti-tumor treatment (whichever comes first).assessed for a maximum duration of up to 1 year
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Scientia Clinical Research Limited
Randwick, New South Wales, Australia
Macquarie University
Sydney, New South Wales, Australia
Icon Cancer Centre South Brisbane
Brisbane, Queensland, Australia
Cancer Research SA
Adelaide, South Australia, Australia
Peninsula & South Eastern Haematology and Oncology Group
Frankston, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.